期刊
BIOMATERIALS
卷 35, 期 19, 页码 5188-5195出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2014.03.032
关键词
Silicon nanowires; Nanocarriers Cancer therapy; Drug resistance; Resistant factor
资金
- National Basic Research Program of China (973 Program) [2013CB934400, 2012CB932400]
- Funds for International Cooperation and Exchange of the National Natural Science Foundation of China [61361160412]
- National Natural Science Foundation of China [30900338, 51072126, 51132006]
- Natural Science Foundation Of Jiangsu Province Of China [BK20130052, BK20130298]
- Specialized Research Fund for the Doctoral Program of Higher Education of China [20133201110019, 20133201120024]
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
Multidrug resistance (MDR) remains a major challenge for cancer treatment thus far. Free doxorubicin (DOX, one of the most widely used chemotherapy agents for cancer treatment) generally features a large value of resistant factor (RF), which is regarded as a significant parameter to assess therapeutic efficiency of cross-resistance. To address this issue, we herein present a kind of silicon nanowires (SiNWs)-based drug nanocarriers (SiNW-DOX), which is high-efficacy for treatment of drug-resistant cancer cells. Typically, drug-resistance cancer cells (e.g., MCF-7/ADR cells) can be significantly inhibited by the SiNWs-based nanocarriers, exhibiting similar to 10% cell viability during 72-h incubation with the SiNWs-DOX (80 mu g mL(-1) DOX), which is in sharp contrast to free DOX-treated cells preserving similar to 40% cell viability. Remarkably, the RF value of SiNW-DOX is as low as similar to 2.0, which is much better than that (similar to 300) of free DOX under the same experiment conditions. To the best of our knowledge, it is the lowest RF value ever reported by nanomaterials-based drug carriers (3.3-24.7). (C) 2014 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据